Merck in-licenses Evaxion vaccine candidate in a deal worth up to $600M
Source: SeekingAlpha
2025-09-25 08:04:48 ET
More on Evaxion Biotech ADS, Merck
- Merck: Undervalued Pharma Stock With Defensive Approach And Compelling Dividend Yield
- Merck: Buy This Dividend Powerhouse While It's Cheap
- Merck & Co., Inc. (MRK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
- Trump administration formally links Tylenol use in pregnancy to autism
- Trump considering website for consumers to buy discounted prescription drugs - report
Read the full article on Seeking Alpha
For further details see:
Merck in-licenses Evaxion vaccine candidate in a deal worth up to $600M
Merck & Company Inc.
NASDAQ: MRK
MRK Trading
1.11% G/L:
$116.48 Last:
2,106,719 Volume:
$116.92 Open:
MRK Latest News
March 05, 2026 10:20:00 am
Forget ImmunityBio: This Big?Cap Pharma Is the Safer Play on Next?Gen Cancer Therapies
March 03, 2026 09:00:00 am
Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion
MRK Stock Data
$291,612,827,755
2,457,202,311
0.02%
2165
N/A
Pharmaceuticals
Healthcare
US
Rahway
